Patents by Inventor Bo Jeong Pyun
Bo Jeong Pyun has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11191801Abstract: The extract of a mixture of cinnamon twig and moutan root bark, cinnamon twig and peony root, or cinnamon twig and poria according to the present invention has been confirmed to inhibit the excessive generation of advanced glycation end-products, which occurs under chronic diabetic conditions, exhibit the effect of fragmentizing a cross-link between the advanced glycation end-products and matrix proteins, have an excellent effect in inhibiting the generation of the advanced glycation end-products in a human retinal pigment epithelial cell line subjected to a hyperglycemic or aging environment, and have excellent effects in delaying, preventing, and treating diabetic complications, muscular degeneration, commotio retinae, and lower extremity edema in various animal models of diabetic complications, macular degeneration, and lower extremity edema, and thus the mixture extract can effectively be used as an active ingredient for a composition for preventing and treating diabetic complications, including diabeticType: GrantFiled: May 21, 2015Date of Patent: December 7, 2021Assignee: KOREA INSTITUTE OF ORIENTAL MEDICINEInventors: Jin Sook Kim, Junghyun Kim, Chan-Sik Kim, Eunjin Shon, Yun Mi Lee, Sojin Choi, Ik Soo Lee, Young Sook Kim, Dong Ho Jung, Bo-Jeong Pyun, Seung-Hyun Jung
-
Patent number: 10537603Abstract: The present invention relates to a pharmaceutical composition for preventing or treating angioedema, containing as an active ingredient a peony root extract or an extract of a mixture of peony root and licorice. In particular, the extract of a mixture of peony root and licorice according to the present invention inhibits the excessive generation of advanced glycation end products, which may cause macular degeneration, inhibits blood-retinal barrier breakdown causing retinal edema in various animal models, protects or treats a subretinal region causing dry macular degeneration, inhibits angiogenesis causing wet macular degeneration, and thus can be usefully used as an active ingredient for the composition for preventing and treating angioedema including macular degeneration, macular edema, retinal edema, or varicose veins.Type: GrantFiled: May 21, 2015Date of Patent: January 21, 2020Assignee: Korea Institute of Oriental MedicineInventors: Jin Sook Kim, Junghyun Kim, Chan-Sik Kim, Eunjin Shon, Yun Mi Lee, Young Sook Kim, Sojin Choi, Ik Soo Lee, Dong Ho Jung, Bo-Jeong Pyun, Seung-Hyun Jung
-
Publication number: 20170209510Abstract: The present invention relates to a pharmaceutical composition for preventing or treating angioedema, containing as an active ingredient a peony root extract or an extract of a mixture of peony root and licorice. In particular, the extract of a mixture of peony root and licorice according to the present invention inhibits the excessive generation of advanced glycation end products, which may cause macular degeneration, inhibits blood-retinal barrier breakdown causing retinal edema in various animal models, protects or treats a subretinal region causing dry macular degeneration, inhibits angiogenesis causing wet macular degeneration, and thus can be usefully used as an active ingredient for the composition for preventing and treating angioedema including macular degeneration, macular edema, retinal edema, or varicose veins.Type: ApplicationFiled: May 21, 2015Publication date: July 27, 2017Inventors: Jin Sook KIM, Junghyun KIM, Chan-Sik KIM, Eunjin SHON, Yun Mi LEE, Young Sook KIM, Sojin CHOI, Ik Soo LEE, Dong Ho JUNG, Bo-Jeong PYUN, Seung-Hyun JUNG
-
Publication number: 20170182107Abstract: The extract of a mixture of cinnamon twig and moutan root bark, cinnamon twig and peony root, or cinnamon twig and poria according to the present invention has been confirmed to inhibit the excessive generation of advanced glycation end-products, which occurs under chronic diabetic conditions, exhibit the effect of fragmentizing a cross-link between the advanced glycation end-products and matrix proteins, have an excellent effect in inhibiting the generation of the advanced glycation end-products in a human retinal pigment epithelial cell line subjected to a hyperglycemic or aging environment, and have excellent effects in delaying, preventing, and treating diabetic complications, muscular degeneration, commotio retinae, and lower extremity edema in various animal models of diabetic complications, macular degeneration, and lower extremity edema, and thus the mixture extract can effectively be used as an active ingredient for a composition for preventing and treating diabetic complications, including diabeticType: ApplicationFiled: May 21, 2015Publication date: June 29, 2017Inventors: Jin Sook KIM, Junghyun KIM, Chan-Sik KIM, Eunjin SHON, Yun Mi LEE, Sojin CHOI, Ik Soo LEE, Young Sook KIM, Dong Ho JUNG, Bo-Jeong PYUN, Seung-Hyun JUNG
-
Patent number: 9572786Abstract: The present invention relates to a new use of capsiate or dihydrocapsiate, more particularly to a composition for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease or for suppressing immunity comprising capsiate, dihydrocapsiate or a pharmaceutically acceptable salt thereof as an effective ingredient. The composition and immunosuppressant of the present invention may be used for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease, and for suppressing immunity.Type: GrantFiled: May 8, 2013Date of Patent: February 21, 2017Assignee: Catholic University Industry Academy Cooperation FoundationInventors: Dong Heun Shin, Young Geun Kwon, Bo Jeong Pyun, Tae-Yoon Kim
-
Patent number: 9381168Abstract: The present invention relates to a new use of capsiate or dihydrocapsiate, more particularly to a composition for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease or for suppressing immunity comprising capsiate, dihydrocapsiate or a pharmaceutically acceptable salt thereof as an effective ingredient. The composition and immunosuppressant of the present invention may be used for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease, and for suppressing immunity.Type: GrantFiled: May 27, 2008Date of Patent: July 5, 2016Assignee: Catholic University Industry Academy Cooperation FoundationInventors: Dong Heun Shin, Young Guen Kwon, Bo Jeong Pyun, Tae-Yoon Kim
-
Patent number: 9249220Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: GrantFiled: March 11, 2014Date of Patent: February 2, 2016Assignee: PHARMABCINE INC.Inventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon-Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
-
Patent number: 9249219Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: GrantFiled: March 11, 2014Date of Patent: February 2, 2016Assignee: PHARMABCINE INC.Inventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon-Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
-
Patent number: 9150650Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: GrantFiled: June 26, 2007Date of Patent: October 6, 2015Assignee: PHARMABCINE INC.Inventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Se-mi Kim, Sang-Seok Koh
-
Publication number: 20140288274Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: ApplicationFiled: March 11, 2014Publication date: September 25, 2014Inventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon-Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
-
Publication number: 20140275488Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: ApplicationFiled: March 11, 2014Publication date: September 18, 2014Applicant: PHARMABCINE INC.Inventors: Jin-San YOO, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong-Eun Kang, Do-Yun Kim, Joon-Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae-Won Jeon, Dong-Sup Lee, Young-Woo Park, Geun-Bae Rha, Hyun-Sook Jang, Hyeon-Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
-
Publication number: 20130245117Abstract: The present invention relates to a new use of capsiate or dihydrocapsiate, more particularly to a composition for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease or for suppressing immunity comprising capsiate, dihydrocapsiate or a pharmaceutically acceptable salt thereof as an effective ingredient. The composition and immunosuppressant of the present invention may be used for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease, and for suppressing immunity.Type: ApplicationFiled: May 8, 2013Publication date: September 19, 2013Applicant: Catholic University Industry Academy Cooperation FoundationInventors: Dong Heun Shin, Young Geun Kim, Bo Jeong Pyun, Tae-Yoon Kim
-
Publication number: 20110065176Abstract: The present invention relates to human monoclonal antibodies neutralizing vascular endothelial growth factor receptor and the use thereof. More specifically, relates to human ScFv molecules neutralizing vascular endothelial growth factor receptor, and a composition for inhibiting angiogenesis and a composition for treating cancer, which contain the human ScFv molecules. The disclosed monoclonal antibody neutralizing vascular endothelial growth factor receptor shows excellent neutralizing ability in living cells, compared to that of a commercially available antibody against vascular endothelial growth factor receptor, and shows the ability to neutralize vascular endothelial growth factor receptor not only in humans, but also in mice and rats. Thus, the monoclonal antibody will be useful in anticancer studies and will be highly effective in cancer treatment.Type: ApplicationFiled: June 26, 2007Publication date: March 17, 2011Applicant: Korea Research Institute of BioScience and BioTechnologyInventors: Jin-San Yoo, Weon-Sup Lee, Sang-Ryeol Shim, Mi-Hee Park, Jeong- Eun Kang, Do-Yun Kim, Joon Chul Lee, Dong-Heon Lee, Too-Hyon Cho, Sam-Sook Sul, Young-Guen Kwon, Bo-Jeong Pyun, Kwi-Hwa Kim, Chae-Ok Yun, Nahm-Ju Kim, Jae -Won Jeon, Dong- Sup Lee, Young-Woo Park, Geun - Bae Rha, Hyun-Sook Jang, Hyeon- Mi Yoo, Sung-Woo Kim, Semi Kim, Sang-Seok Koh
-
Publication number: 20110028547Abstract: The present invention relates to a new use of capsiate or dihydrocapsiate, more particularly to a composition for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease or for suppressing immunity comprising capsiate, dihydrocapsiate or a pharmaceutically acceptable salt thereof as an effective ingredient. The composition and immunosuppressant of the present invention may be used for preventing and treating inflammatory disease, angiogenesis-related disease and autoimmune disease, and for suppressing immunity.Type: ApplicationFiled: May 27, 2008Publication date: February 3, 2011Applicant: Catholic University Industry Academic CooperationInventors: Dong Heun Shin, Young Guen Kwon, Bo Jeong Pyun, Tae-Yoon Kim